Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

150.09 USD -4.93 (-3.18%)
Official Closing Price Updated: 5:39 PM EST, Feb 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,022,188
Open 154.21
Bid (Size) 148.00 (1)
Ask (Size) 151.90 (2)
Prev. Close 155.02
Today's Range 148.36 - 156.31
52wk Range 90.57 - 213.94
Shares Outstanding 158,224,428
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
- Submissions will be Reviewed Under Real-Time Oncology Review Based on Clinical Trials EV-301 and Cohort 2 of EV-201 - 
From PR Newswire
Seagen to Present at the Cowen 41st Annual Healthcare Conference
Seagen Inc. (Nasdaq: SGEN) today announced that management will participate in a fireside chat at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 2:40 p.m. Eastern Time. The... 
From Business Wire News Releases

Performance

YTD
-10.89%
-10.89%
1 Month
-16.67%
-16.67%
3 Month
-9.28%
-9.28%
6 Month
-2.84%
-2.84%
1 Year
+33.56%
+33.56%

More News

Read More
Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
From PR Newswire
Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplat
From PR Newswire
Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer
From Business Wire News Releases
Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplat
From Business Wire News Releases
Why Merck Is Buying Autoimmune Disease Drug Company Pandion For $1.85B
Tags Benzinga M&A News
From Benzinga
Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
From Business Wire News Releases
Analysts Expect QQQ To Hit $355
Tags ETFs
From ETF Channel
Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment
Tags MRK SGEN oncology
From Benzinga
Seagen/Astellas Pharma Seek Approval For PADCEV's Expanded Use In Urothelial Cancer Settings
Tags ALPMY FDA Market News
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.